Background. Asthenic syndrome (AS) occurs in the practice of doctors of all specialties, and its frequency and prevalence tend to steadily increase, especially among young and middle-aged population groups. Therapy for AS should be carried out in accordance with the etiological factors and the main clinical manifestations; however, the correction of asthenic manifestations continues to be a complex medical problem.
Objective. Evaluation of the clinical effectiveness and safety of using the phenylpiracetam (Actitropil) in patients with AS.
Methods. An open, observational, prospective, non-comparative, non-randomized study included 50 patients aged 18 to 30 years (mean age 24.7±5.4 years), with clinical manifestations of reactive asthenia lasting from 3 to 6 months. Patients received Actitropil at a dose of 200 mg/day. The duration of therapy was 30 days, the total follow-up period was 60 days.
Results. The results of the study showed the high effectiveness and safety of Actitropil in the treatment of AS. During therapy, by the end of the 1st month of treatment, the severity of AS significantly decreased according to the MFI-20 (from 76.0±5.5 to 58.0±6.2 points; P<0.05) and WAM scales, and psychoemotional state has improved (total HADS score decreased from 16.1±4.7 to 12.2±3.9; P<0.05) as well as and sleep (dynamics on the Spiegel scale from 16.9±2.1 to 20.9 ±2.1; P<0.05). The drug was well tolerated and had no side effects.
Conclusion. Actitropil at a dose of 200 mg/day for a month can be recommended for the treatment of AS, in particular for the correction of clinical manifestations of reactive asthenia in young people as monotherapy.

Keywords: phenylpiracetam, chronic fatigue syndrome, asthenic syndrome, fatigue